On November 18, Twist Bioscience Corp rose 4.06% in Regular Trading, trading near $109.185 per share, with turnover of $81.2743 million.
The move came as the market continued to digest the company’s recent earnings and slowing AI drug discovery growth outlook, while analyst views turned more divided after several target-price cuts were followed by a higher target from Piper Sandler.
Twist Bioscience Corp previously reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus. Fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, investors focused on management’s indication that AI drug discovery-related growth could slow. Recent analyst actions included target reductions to $120 at UBS, $125 at Jefferies, and $150 at Guggenheim, while Piper Sandler raised its target to $140 from $115, reflecting a clearer split in institutional views and helping explain the stock’s continued volatility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments